Cullgen Inc. (“Cullgen”), a privately-held, clinical-stage biopharmaceutical company applying its proprietary targeted protein degradation uSMITE™ platform to discover and advance therapeutics for the ...
SAN DIEGO, CA and SOUTH SAN FRANCISCO, CA / / January 21, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ('Dermata') and Revance Therapeutics, Inc. (Nasdaq: RVNC) ('Revance' together ...